BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36631092)

  • 1. A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance.
    Adachi K; Kato S; Koshino A; Nagao K; Sugiyama T; Yoshimine T; Yamaguchi Y; Izawa S; Ohashi W; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    Intern Med; 2023 Aug; 62(16):2301-2306. PubMed ID: 36631092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant
    Sue S; Suzuki Y; Sasaki T; Kaneko H; Irie K; Komatsu K; Maeda S
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line
    Sue S; Suzuki N; Shibata W; Sasaki T; Yamada H; Kaneko H; Tamura T; Ishii T; Kondo M; Maeda S
    Gastroenterol Res Pract; 2017; 2017():2019802. PubMed ID: 29181022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Sue S; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    JGH Open; 2021 Feb; 5(2):307-311. PubMed ID: 33553672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of vonoprazan-based rescue therapy for
    Yu J; Lv YM; Yang P; Jiang YZ; Qin XR; Wang XY
    World J Gastroenterol; 2023 May; 29(20):3133-3144. PubMed ID: 37346155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
    Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
    Miyaki A; Yamaguchi K; Ida A; Miyauchi T
    Minerva Gastroenterol Dietol; 2016 Sep; 62(3):234-9. PubMed ID: 27304198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection.
    Matsushima M; Suzuki T; Kurumada T; Watanabe S; Watanabe K; Kobayashi K; Deguchi R; Masui A; Takagi A; Shirai T; Muraoka H; Kobayashi I; Mine T
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):232-6. PubMed ID: 16460479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
    Sue S; Maeda S
    Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
    Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.